Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 27;64(5):e202417272.
doi: 10.1002/anie.202417272. Epub 2024 Dec 16.

A Kinetic Scout Approach Accelerates Targeted Protein Degrader Development

Affiliations

A Kinetic Scout Approach Accelerates Targeted Protein Degrader Development

Angela T Fan et al. Angew Chem Int Ed Engl. .

Abstract

Bifunctional molecules such as targeted protein degraders induce proximity to promote gain-of-function pharmacology. These powerful approaches have gained broad traction across academia and the pharmaceutical industry, leading to an intensive focus on strategies that can accelerate their identification and optimization. We and others have previously used chemical proteomics to map degradable target space, and these datasets have been used to develop and train multiparameter models to extend degradability predictions across the proteome. In this study, we now turn our attention to develop generalizable chemistry strategies to accelerate the development of new bifunctional degraders. We implement lysine-targeted reversible-covalent chemistry to rationally tune the binding kinetics at the protein-of-interest across a set of 25 targets. We define an unbiased workflow consisting of global proteomics analysis, IP/MS of ternary complexes and the E-STUB assay, to mechanistically characterize the effects of ligand residence time on targeted protein degradation and formulate hypotheses about the rate-limiting step of degradation for each target. Our key finding is that target residence time is a major determinant of degrader activity, and this can be rapidly and rationally tuned through the synthesis of a minimal number of analogues to accelerate early degrader discovery and optimization.

Keywords: PROTACs; Targeted protein degradation; compound residence time; proteasomal degradation; proteomics.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement:

K.A.D receives or has received consulting fees from Kronos Bio and Neomorph Inc. W.R.S. and H.H. are patent holders on a patent application for the E-STUB technology. W.R.S. is a Board or SAB member and holds equity in Delphia Therapeutics, Ideaya Biosciences, Red Ridge Bio, Scorpion Therapeutics and has consulted for Array, Astex, CJ Biosciences, Epidarex Capital, Ipsen, Merck Pharmaceuticals, Pierre Fabre, Sanofi, Servier and Syndax Pharmaceuticals and receives research funding from Bayer Pharmaceutical, Bristol-Myers Squibb, Boehringer-Ingelheim, Ideaya Biosciences, Calico Biosciences, and Servier Pharmaceuticals. W.R.S. is a co-patent holder on EGFR mutation diagnostic patents. F.M.F. is a scientific co-founder and equity holder in Proximity Therapeutics, and was previously a scientific advisory board member (SAB) of Triana Biomedicines. F.M.F. is or was recently a consultant or received speaking honoraria from RA Capital, Eli Lilly and Co., Sorrento Pharma, Plexium Inc, Sygnature Discovery, Neomorph Inc. and Tocris BioTechne. The Ferguson lab receives or has received research funding or resources in kind from Ono Pharmaceutical Co. Ltd, Promega Corp, Eli Lilly and Co., and Merck and Co. F.M.F.’s interests have been reviewed and approved by the University of California San Diego in accordance with its conflict-of-interest policies. E.S.F. is a founder, scientific advisory board (SAB) member, and equity holder of Civetta Therapeutics, Proximity Therapeutics, Stelexis Biosciences, and Neomorph, Inc. (also board of directors). He is an equity holder and SAB member for Avilar Therapeutics, Photys Therapeutics, and Ajax Therapeutics and an equity holder in Lighthorse Therapeutics and Anvia Therapeutics. E.S.F. is a consultant to Novartis, EcoR1 capital, Odyssey and Deerfield. The Fischer lab receives or has received research funding from Deerfield, Novartis, Ajax, Interline, Bayer and Astellas. C.C. is an employee of Johnson and Johnson.

Update of

References

    1. Whelan R & Mayor-Ruiz C Chemical rewiring of ubiquitination by degraders and their selectivity routes. Nat Struct Mol Biol 31, 205–207 (2024). 10.1038/s41594-024-01215-8 - DOI - PubMed
    1. O'Brien Laramy MN, Luthra S, Brown MF & Bartlett DW Delivering on the promise of protein degraders. Nat Rev Drug Discov 22, 410–427 (2023). 10.1038/s41573-023-00652-2 - DOI - PubMed
    1. Burslem GM & Crews CM Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery. Cell 181, 102–114 (2020). 10.1016/j.cell.2019.11.031 - DOI - PMC - PubMed
    1. Cowan AD & Ciulli A Driving E3 Ligase Substrate Specificity for Targeted Protein Degradation: Lessons from Nature and the Laboratory. Annu Rev Biochem 91, 295–319 (2022). 10.1146/annurev-biochem-032620-104421 - DOI - PubMed
    1. Donovan KA et al. Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell 183, 1714–1731 e1710 (2020). 10.1016/j.cell.2020.10.038 - DOI - PMC - PubMed

LinkOut - more resources